Advertisement
Advertisement
U.S. Markets close in 5 hrs 33 mins
Advertisement
Advertisement
Advertisement
Advertisement

CareDx, Inc (CDNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
39.32+0.35 (+0.89%)
As of 10:22AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close38.97
Open39.30
Bid39.69 x 800
Ask40.10 x 800
Day's Range39.17 - 40.44
52 Week Range38.22 - 99.83
Volume76,295
Avg. Volume795,474
Market Cap2.076B
Beta (5Y Monthly)0.56
PE Ratio (TTM)N/A
EPS (TTM)-0.35
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est99.33
  • GuruFocus.com

    Mesirow Financial Investment Management, Inc. ...

    Investment company Mesirow Financial Investment Management, Inc. (Current Portfolio) buys Green Brick Partners Inc, Cadre Holdings Inc, Identiv Inc, Atlanticus Holdings Corp, Andersons Inc, sells TriState Capital Holdings Inc, The Joint Corp, Mirum Pharmaceuticals Inc, Genasys Inc, CareDx Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Mesirow Financial Investment Management, Inc..

  • GlobeNewswire

    Landmark ADMIRAL Study Publication with CareDx’s AlloSure Kidney is the First Long-Term Multicenter Prospective Clinical Validation for Routine Organ Transplant Surveillance

    ADMIRAL Study Shows AlloSure Detects Clinical and Subclinical ABMR and TCMR, and Predicts Long-Term Outcomes for Kidney Transplant Patients AlloSure Showed 62% Improvement Over Standard of Care Serum Creatinine SOUTH SAN FRANCISCO, Calif., Jan. 12, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced the pub

  • GlobeNewswire

    CareDx Partners with Multiple Biotechnology Companies to Use AlloCell in CAR T-Cell Therapy Clinical Studies

    AlloCell Will Be Used to Monitor the Expansion and Persistence of Allogeneic Cell Therapies in Clinical Development for Use in OncologySOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced recent drug development collaborations with three leading cell thera

Advertisement
Advertisement